Bright Minds Biosciences (DRUG) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $51.30, -5.37% vs the prior close of $54.21.
- Volume 56.03K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DRUG slides 5.4% to $51.30. Closed at $51.30, -5.37% vs the prior close of $54.21. Day range $51.30–$54.15, opened at $54.15.
DRUG daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DRUG slides 5.4% to $51.30
- Closed at $51.30, -5.37% vs the prior close of $54.21. Day range $51.30–$54.15, opened at $54.15.
- Volume was 56.03K shares, 0.4x its 50-day average of 129.96K — lighter than usual.
- Price is -20.4% vs its 50-day average ($64.47) and -31.6% vs its 200-day average ($74.96).
- 52-week range $47.23–$123.75; today's close sits at 5% of that range, 58.5% below the 52-week high.
Oct 15, 2026 — DRUG jumps 6.9% to $54.21
- Closed at $54.21, +6.90% vs the prior close of $50.71. Day range $51.24–$55.75, opened at $51.80.
- Volume was 121.50K shares, 0.9x its 50-day average of 129.87K.
- Price is -16.7% vs its 50-day average ($65.06) and -27.8% vs its 200-day average ($75.08).
- 52-week range $47.23–$123.75; today's close sits at 9% of that range, 56.2% below the 52-week high.
Oct 14, 2026 — DRUG dips 1.3% to $50.71, 3 down days in a row
- Closed at $50.71, -1.27% vs the prior close of $51.36. Day range $49.06–$52.96, opened at $50.52.
- Volume was 199.40K shares, 1.5x its 50-day average of 129.23K.
- Price is -22.7% vs its 50-day average ($65.57) and -32.6% vs its 200-day average ($75.20).
- 52-week range $47.23–$123.75; today's close sits at 5% of that range, 59.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — DRUG slides 4.9% to $51.36 on 1.9x normal volume
- Closed at $51.36, -4.91% vs the prior close of $54.01. Day range $50.99–$54.35, opened at $54.01.
- Volume was 246.60K shares, 1.9x its 50-day average of 129.82K — unusually heavy trading.
- Price is -22.3% vs its 50-day average ($66.11) and -31.8% vs its 200-day average ($75.36).
- 52-week range $47.23–$123.75; today's close sits at 5% of that range, 58.5% below the 52-week high.
Oct 12, 2026 — DRUG ends flat (-0.1%) to $54.01
- Closed at $54.01, -0.07% vs the prior close of $54.05. Day range $53.27–$55.20, opened at $53.89.
- Volume was 134.60K shares, 1.0x its 50-day average of 131.38K.
- Price is -18.8% vs its 50-day average ($66.55) and -28.5% vs its 200-day average ($75.53).
- 52-week range $47.23–$123.75; today's close sits at 9% of that range, 56.4% below the 52-week high.
Oct 9, 2026 — DRUG jumps 3.9% to $54.05
- Closed at $54.05, +3.94% vs the prior close of $52.00. Day range $51.91–$55.78, opened at $52.45.
- Volume was 98.40K shares, 0.7x its 50-day average of 133.55K.
- Price is -19.3% vs its 50-day average ($66.94) and -28.6% vs its 200-day average ($75.68).
- 52-week range $47.23–$123.75; today's close sits at 9% of that range, 56.3% below the 52-week high.
Oct 8, 2026 — DRUG ends flat (+0.0%) to $52.00
- Closed at $52.00, +0.00% vs the prior close of $52.00. Day range $49.29–$52.64, opened at $51.01.
- Volume was 67.90K shares, 0.5x its 50-day average of 136.13K — lighter than usual.
- Price is -22.8% vs its 50-day average ($67.35) and -31.4% vs its 200-day average ($75.82).
- 52-week range $47.23–$123.75; today's close sits at 6% of that range, 58.0% below the 52-week high.
Oct 7, 2026 — DRUG jumps 7.8% to $52.00 on 5.4x normal volume
- Closed at $52.00, +7.77% vs the prior close of $48.25. Day range $47.23–$53.01, opened at $47.23.
- Volume was 688.80K shares, 5.4x its 50-day average of 127.12K — unusually heavy trading.
- Price is -23.2% vs its 50-day average ($67.73) and -31.6% vs its 200-day average ($75.98).
- 52-week range $47.23–$123.75; today's close sits at 6% of that range, 58.0% below the 52-week high.
Oct 6, 2026 — DRUG slides 3.1% to $48.25, a 52-week low
- Closed at $48.25, -3.09% vs the prior close of $49.79. Day range $47.60–$50.00, opened at $49.79.
- Volume was 107.70K shares, 0.8x its 50-day average of 128.86K.
- Price is -29.2% vs its 50-day average ($68.13) and -36.6% vs its 200-day average ($76.12).
- 52-week range $47.60–$123.75; today's close sits at 1% of that range, 61.0% below the 52-week high.
Oct 5, 2026 — DRUG dips 1.8% to $49.79
- Closed at $49.79, -1.78% vs the prior close of $50.69. Day range $49.08–$51.33, opened at $50.69.
- Volume was 55.90K shares, 0.4x its 50-day average of 134.66K — lighter than usual.
- Price is -27.4% vs its 50-day average ($68.60) and -34.8% vs its 200-day average ($76.32).
- 52-week range $48.53–$123.75; today's close sits at 2% of that range, 59.8% below the 52-week high.
Oct 2, 2026 — DRUG jumps 3.0% to $50.69
- Closed at $50.69, +3.01% vs the prior close of $49.21. Day range $48.75–$51.04, opened at $49.61.
- Volume was 154.90K shares, 1.1x its 50-day average of 136.52K.
- Price is -26.6% vs its 50-day average ($69.03) and -33.8% vs its 200-day average ($76.54).
- 52-week range $48.53–$123.75; today's close sits at 3% of that range, 59.0% below the 52-week high.
- SEC filings that day: 6-K.
DRUG latest news & SEC filings
Every SEC filing by or about DRUG in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 1, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 17, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade DRUG
- How much it moves: over the last 20 sessions the average daily move was 3.17% (largest 7.8%). That is a volatile stock.
- Liquidity: about 147.75K shares (≈$7.58M) trade per day on average.
- 52-week position: $51.30 vs a range of $47.23–$123.75 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 12 sales; latest: Asset Management, Lp Cormorant sold 109,331 shares on Apr 28, 2026.
- Latest filings: 6-K Oct 2, 2026; 6-K Oct 1, 2026; 6-K Aug 17, 2026.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
DRUG market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 54.15 | 54.15 | 51.30 | 51.30 | 56.03K |
| Oct 15, 2026 | 51.80 | 55.75 | 51.24 | 54.21 | 121.50K |
| Oct 14, 2026 | 50.52 | 52.96 | 49.06 | 50.71 | 199.40K |
| Oct 13, 2026 | 54.01 | 54.35 | 50.99 | 51.36 | 246.60K |
| Oct 12, 2026 | 53.89 | 55.20 | 53.27 | 54.01 | 134.60K |
| Oct 9, 2026 | 52.45 | 55.78 | 51.91 | 54.05 | 98.40K |
| Oct 8, 2026 | 51.01 | 52.64 | 49.29 | 52.00 | 67.90K |
| Oct 7, 2026 | 47.23 | 53.01 | 47.23 | 52.00 | 688.80K |
| Oct 6, 2026 | 49.79 | 50.00 | 47.60 | 48.25 | 107.70K |
| Oct 5, 2026 | 50.69 | 51.33 | 49.08 | 49.79 | 55.90K |
| Oct 2, 2026 | 49.61 | 51.04 | 48.75 | 50.69 | 154.90K |
| Oct 1, 2026 | 49.54 | 52.12 | 48.53 | 49.21 | 166.90K |
| Sep 30, 2026 | 50.00 | 50.96 | 49.01 | 49.82 | 79.80K |
| Sep 29, 2026 | 53.17 | 53.17 | 49.53 | 49.74 | 96.80K |
| Sep 28, 2026 | 52.69 | 52.69 | 49.55 | 51.66 | 91.90K |
| Sep 25, 2026 | 53.33 | 54.37 | 51.41 | 51.80 | 211.00K |
| Sep 24, 2026 | 57.91 | 58.30 | 52.90 | 53.51 | 129.60K |
| Sep 23, 2026 | 60.44 | 60.44 | 56.50 | 57.92 | 90.40K |
| Sep 22, 2026 | 60.36 | 62.45 | 60.15 | 60.67 | 65.30K |
| Sep 21, 2026 | 61.98 | 61.98 | 59.17 | 59.46 | 91.60K |
About Bright Minds Biosciences
Bright Minds Biosciences (DRUG) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CHICAGO, IL. State of incorporation: British Columbia, Canada. Fiscal year ends September 30. SEC CIK 1827401.
DRUG board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| No Form 3/4/5 filings by this group in the last 12 months. | ||
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Apr 28, 2026 | Asset Management, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Asset Management, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Global Healthcare Master Fund, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Global Healthcare Master Fund, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Bihua Chen | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Bihua Chen | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Asset Management, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Asset Management, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Global Healthcare Master Fund, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Global Healthcare Master Fund, Lp Cormorant | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Bihua Chen | Sale | 109,331 | $89.50 |
| Apr 28, 2026 | Bihua Chen | Sale | 109,331 | $89.50 |
DRUG financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
DRUG earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DRUG
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.